Join the VESIcare group to help and get support from people like you.
VESIcare News
FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients
NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA)...
FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
TOKYO, May 7, 2018 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved...
Further information
Related condition support groups
Overactive Bladder, Urinary Incontinence